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C-reactive protein (CRP) is a member 
of the pentraxin protein family which 
have a native pentameric ring structure 
made up of 5 non-covalently 
associated monomers. It is an acute 
phase protein produced predominantly 
in the liver with plasma levels 
increasing up to 10,000-fold in 
response to infection. CRP is widely 
used as a marker of cardiovascular 
disease [1] and has been implicated in 
its pathogenesis [2], although its exact 
role is unclear [3]. While circulating 
CRP exists in the native pentameric 
form (pCRP) it can also exist in a 
modified monomeric form (mCRP). 
These two distinct forms of CRP have 
been demonstrated to have opposing 
biological actions.  
 
CRP has been shown to modulate the 
interaction between platelets and 
neutrophils [4, 5]. mCRP was 
demonstrated to enhance the 
interaction under shear via an 
interaction with P-selectin and CD18 
while pCRP inhibited the interaction 
via an interaction with the FcγRIIa [5]. 
Heuertz et al. demonstrated that 
mCRP interacted with CD16 (FcγRIIIb) 
on neutrophils, but not with CD32 
(FcγRIIa) [6].  
 
CRP has been associated with 
procoagulant [7] and anti-fibrinolytic 
activity [8] and has also been shown to 
have diverse effects on platelets. 
While heat-agglutinated CRP [9] and 
mCRP [10] have been shown to 
activate platelets pCRP has been 
shown to inhibit platelet aggregation by 
a range of agonists [11, 12, 13]. The 
mechanism by which pCRP inhibits 
platelet aggregation is unknown and 
this study was designed to elucidate 
the mechanism of platelet inhibition 
using platelet adhesion and purified 
protein ELISA based assays.  
 
Platelet adhesion and aggregation 
studies were performed as previously 
described [14]. For this study we used 
healthy volunteers who had not taken 
any non-steroidal anti-inflammatories 
for a fortnight and did not discriminate 
based on age or sex. Ethical approval 
was obtained from the RCSI ethics 
committee. As with previous studies 
we found that recombinant pCRP 
(Calbiochem, Darmstadt, Germany, 
10µg/ml) inhibited platelet aggregation 
induced by low-dose thrombin receptor 
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activating peptide, (TRAP, 2-4µM), 
collagen (38µg/ml) and ADP (1-5µM) 
by 72% ± 10%, 95% ± 2% and 91% ± 
4% respectively (P<0.001 for all) 
indicating an agonist-independent 
effect of pCRP, similar to that seen 
with αIIbβ3 inhibitors. To determine if 
there was a direct interaction between 
CRP and platelets, we investigated the 
ability of washed platelets to bind to 
immobilised CRP. Resting platelets 
adhered strongly to fibrinogen and to a 
lesser extent to CRP (30% ± 7% of the 
fibrinogen control, fig. IA).  
 
As αIIbβ3 is a key receptor in platelet 
aggregation and adhesion we 
investigated its ability to bind CRP. 
Mn2+ alters the conformation of αIIbβ3 
increasing its affinity for RGD 
containing peptide ligands [15]. This is 
not as strong as other agonists and 
does not lead to signalling which would 
lead to granule release and platelet 
shape change. All other agonists 
signal into the platelet (outside-in 
signalling), and lead not only to 
granule release, but also an increase 
in P-selectin expression. Thus due to 
the reports that CRP interacts with P-
selectin [4, 5], we might see increased 
platelet adhesion or at least αIIbβ3-
independent adhesion if platelets 
activated with soluble agonists were 
used. The use of MnCl2 allows us to 
look at the αIIbβ3 interaction without the 
complications of the P-selectin 
interaction. 
Direct activation of αIIbβ3, using MnCl2 
(1mM) had little effect on platelet 
adhesion to fibrinogen but increased 
adhesion to CRP approximately 4-fold 
(128 ± 6% of fibrinogen control, 
P<0.001). Tirofiban, a specific αIIbβ3 
antagonist [16] (1µM) completely 
inhibited both resting and activated 
platelet adhesion to fibrinogen (from 
100% to 3% ± 6% (resting) and from 
99% ± 3% to 3% ± 9% (MnCl2 
activated), P<0.001 for both). Tirofiban 
inhibited resting platelet adhesion to 
CRP by 43% (from 30% ± 7% to 17 ± 
2%), although this inhibition was not 
statistically significant due to the 
variation observed in this assay at low 
levels of adhesion. Tirofiban 
completely inhibited the adhesion of 
MnCl2-activated platelets to CRP (from 
128 ± 6% to 0 ± 12%, P<0.001).  
 
To confirm a direct interaction with 
αIIbβ3, we utilized an ELISA to 
measure binding of purified αIIbβ3 to 
CRP (fig. IB). These data directly 
mirrored the results from the platelet 
adhesion study with adhesion of 
resting αIIbβ3 to CRP at 36% ± 6% of 
the adhesion to fibrinogen. This was 
also increased 4-fold to 133% ± 25% 
with MnCl2 activation of αIIbβ3 
(P<0.001). Tirofiban strongly inhibited 
purified αIIbβ3 adhesion to CRP 
(Resting: from 36% ± 6% to 2% ± 3%, 
P=NS; MnCl2 activated αIIbβ3: from 
133% ± 25% to 14% ± 6%, P<0.001). 
We also investigated a role for the 
FcγRIIa due to its role in immune-
mediated platelet activation [14, 17] 
and previous reports of an interaction 
between the FcγRIIa and pCRP. 
Neither adhesion to fibrinogen nor 
CRP was inhibited by the monoclonal 
antibody to the FcγRIIa, (IV.3) (data 
not shown), suggesting that this 
receptor does not play a role in platelet 
adhesion to CRP.  
 
We have demonstrated that 
immobilized CRP can support platelet 
adhesion and that it has a higher 
affinity for manganese-treated platelets 
suggesting a greater affinity for the 
activated form of αIIbβ3. In support of 
this, we have demonstrated that 
immobilized CRP interacts directly with 
purified αIIbβ3, and also has increased 
binding to manganese activated αIIbβ3 
in this system. This interaction was 
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inhibited by tirofiban, suggesting that 
CRP interacts with αIIbβ3 through the 
RGD binding site. Analysis of the 
surface exposed residues of CRP 
identified the RGD-like motif, 58RQD60. 
Thus it is possible that this sequence 
could be responsible for the interaction 
with αIIbβ3 which we have 
demonstrated.  
 
These data may explain previous 
reports on the platelet inhibitory activity 
of pCRP. Recently, pCRP was shown 
to decrease fibrinogen binding to 
platelets pre-activated with ADP [19] 
which our data would suggest is due to 
direct binding of pCRP to αIIbβ3. We 
suggest that soluble pCRP can interact 
with activated αIIbβ3, blocking 
fibrinogen binding thus acting as an 
αIIbβ3 antagonist in a soluble setting. 
This is likely to be relevant in 
conditions associated with infection 
[17] or inflammation where the high 
levels of pCRP may act to suppress 
platelet aggregation. Atherosclerosis is 
probably influenced more by mCRP 
interactions with the vessel wall. We 
cannot exclude the possibility of an 
interaction between mCRP and αIIbβ3. 
Previous reports have suggested that 
pCRP changes conformation upon 
binding to cationic surfaces [18] and 
pCRP bound to membranes has been 
shown to undergo a transition to 
mCRPm and then to mCRPs (REF). 
Taking into consideration the ability of 
soluble pCRP to inhibit aggregation 
induced by wide range of platelet 
agonists and its ability to support 
platelet adhesion when immobilised  it 
is possible that both pCRP and mCRP 
can directly interact with αIIbβ3.  
 
In conclusion we have shown that 
CRP at levels found during episodes of 
inflammation directly binds to the 
activated form of αIIbβ3 and inhibits 
platelet aggregation. 
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Activation Treatment Platelet adhesion GPIIb/IIIa ELISA 
  
Fibrinogen CRP Fibrinogen CRP 
No drug 1.00 ± 0.14 0.32 ± 0.11 0.24 ± 0.04 0.09 ± 0.02 
Resting 
Tirofiban 0.04 ± 0.07 P<0.001 
0.17 ± 0.04 
NS 
0.00 ± 0.01 
P<0.001 
0.01 ± 0.01 
NS 
No drug 0.99 ± 0.17 1.30 ± 0.24 0.47 ± 0.04 0.30 ± 0.04 
MnCl2  
treated Tirofiban 0.05 ± 0.11 P<0.001 
0.00 ± 0.12 
P<0.001 
0.01 ± 0.01 
P<0.001 
0.03 ± 0.02 
P<0.001 
 
 
Figure I: Platelets and purified αIIbβ3 adhere to immobilized pCRP. A Platelet 
adhesion to pCRP is potentiated by manganese activation of platelets and inhibited 
by αIIbβ3 antagonists. B Purified αIIbβ3 adhered to immobilized pCRP in an ELISA 
based assay. Plates were coated with fibrinogen or pCRP (50 µg/ml) by incubating 
protein solutions in the wells for 2h at 37 °C, and further blocked with 1% BSA. 
Resting (washed) platelets (A) or purified αIIbβ3 (B) were treated with 1 mM MnCl2 for 
10 min prior to adhesion. Where indicated, platelets or purified protein were 
incubated with tirofiban (1 µM) for 10 min prior to adhesion to immobilized pCRP or 
fibrinogen. For the ELISA assay, (B), 50 µg/ml αIIbβ3 (Calbiochem, Darmstadt, 
Germany) was incubated with the plates for 1 hour. Anti-CD41 clone SZ22 (2 µg/ml) 
was incubated for 90 min and HRP-conjugated goat anti-mouse (Pierce, Rockford, 
IL) (1/15000) for 45 min. Values were normalized to the fibrinogen control (resting). 
Data is represented as the mean ± SEM. Statistics were carried out prior to 
normalization using repeated measures ANOVA with Bonferroni’s correction for 
multiple comparisons (* represents P<0.001, n=3). Absolute values for the platelet 
adhesion assay (absorbance 405 nm) and the GPIIb/IIIa ELISA assay  (absorbance 
450 nm) are tabulated below (C). 
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Fg + resting platelets
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CRP + resting platelets
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